A Long-Term Study of JNS007ER in Patients With Schizophrenia

Inclusion Criteria: * Patients diagnosed with schizophrenia * Patients who have given their own consent in writing to participate in the study * Patients untreated with antipsychotics within 28 days before the screening test * Patients who have completed Study JNS007ER-JPN-S31, or those who continued the study at least up to the evaluation at 2 weeks and subsequently discontinued the study due to insufficient efficacy * Patients participating in Study JNS007ER-JPN-S31 and whose ratio of treatment to the evaluation at 2 weeks is ≥75% Exclusion Criteria: * Patients diagnosed with a mental disease other than schizophrenia * A total PANSS score \> 120 at baseline * Substance-related disorders * Parkinson's disease complications * Current or a past history of convulsive disease such as epilepsy * Current or a past history of cerebrovascular accident * Diabetes mellitus * Significant hepatic or renal impairment * Significant cardiovascular disorders * Abnormal results of hematological examination, blood chemistry test and urinalysis at screening * Pregnant women, breast-feeding mothers, and patients who wish pregnancy during the study period or those whose pregnancy test at screening was positive * Contraindications to risperidone products * Patients who discontinued Study JNS007ER-JPN-S31 due to an adverse event not related to the underlying disease * Patients judged inadequate by the investigator to participate in the study